Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

53.23 +0.76 (+1.44%)
Streaming Delayed Price Updated: 11:20 AM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,305,669
Open 52.58
Bid (Size) 53.22 (12)
Ask (Size) 53.23 (4)
Prev. Close 52.47
Today's Range 52.48 - 53.70
52wk Range 38.48 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 2.93%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pfizer, BioNTech Say Three-Dose Covid Vaccine Is 80% Effective In Children Under 5
Pfizer tested a three-dose vaccine in nearly 1,700 children. 
Via Investor's Business Daily
Morning Brief: Top Financial Stories Dominating on Monday, May 23
CNBC US Announces Asia Economic Deal To Strengthen Foothold, Check China 
Via Benzinga

Performance

YTD
-6.05%
-6.05%
1 Month
+10.59%
+10.59%
3 Month
+11.98%
+11.98%
6 Month
+3.96%
+3.96%
1 Year
+33.70%
+33.70%

More News

Read More
European Regulator Approves AstraZeneca's COVID-19 shot As Booster
Via Benzinga
Pfizer-BioNTech's Third COVID-19 Vaccine Shot Shows 80% Efficacy In Youngest Children
Via Benzinga
Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections
Via Benzinga
Read Why Pfizer Is Limiting Supply Of Paxlovid For Combination Studies: Bloomberg
Via Benzinga
FDA Declines Emergency Use Request For An Antidepressant As COVID-19 Treatment
Via Benzinga
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
From Pfizer Inc.
Via Business Wire
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
Online shop Etalaze announces shift to a new domain www.Etalaze.biz
Via AB Newswire
Mystery Solved! The Top 9 Bestselling Products In History
Via Benzinga
This Is What Whales Are Betting On Pfizer
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, May 20
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years
Via Benzinga
5 Oversold Blue-Chip Stocks to Buy Right Now
Via InvestorPlace
North Carolina Physicians' Group Calls for Halt to Atrium COVID Vaccine Trial for Children
Via Newswire.com
Topics Death
Exposures COVID-19 Death
Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics
Via Benzinga
Looking At Pfizer's Recent Whale Trades
Via Benzinga
Thoughts For Thursday: Ugly and Uglier
Via Talk Markets
3 Safe Stocks to Buy As We Head For a Recession
Via Talk Markets
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Via Benzinga
EXCLUSIVE: Be The House Not The Gambler — How To Use Options To Improve Performance
Via Benzinga
FDA Gives Green Signal To Pfizer/BioNTech's COVID-19 Booster For Kids 5-11 Years
Via Benzinga
Awardees named for $20 million project to foster diversity in clinical trial research
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.